Madrigal Pharmaceuticals vs Tilray Brands
Madrigal Pharmaceuticals reported revenue of $958 million in fiscal 2025, about the same as Tilray Brands' $916 million in fiscal 2026. Madrigal Pharmaceuticals' revenue grew 432.1% in its latest year, and Tilray Brands' grew 11.5%. Madrigal Pharmaceuticals had an operating margin of -31.3%, against -6.9% at Tilray Brands. Their fiscal years end in different months (December 31 and May 31), so the periods don't line up exactly.
Side by side
| Madrigal Pharmaceuticals | Tilray Brands | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, May 31, 2026 |
| Revenue | $958M | $916M |
| Revenue growth | 432.1% | 11.5% |
| Revenue growth a year, last 5 years | — | 12.3% |
| Gross margin | — | 28.4% |
| Operating margin | −31.3% | −6.9% |
| Net margin | −30.1% | −13.3% |
| Free cash flow | −$190M | — |
| Free cash flow margin | −19.8% | — |
| Return on capital | — | −3.4% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 5.5% | 25.6% |
| Last close | $396.74 | $2.07 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $69.0 million | bought $69,225, sold $232,879 |
| Piotroski F-score | 3 of 8 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Madrigal PharmaceuticalsTilray Brands
Operating margin
Percent of revenue
Madrigal PharmaceuticalsTilray Brands
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Madrigal PharmaceuticalsTilray Brands
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Madrigal Pharmaceuticals and Tilray Brands pages.